IDO/Tubulin-IN-2 (HT2) is a powerful inhibitor of both TDO and tubulin. This compound demonstrates significant efficacy against various cancer cell lines, including U87, HepG2, A549, HCT-116, and LO2, with respective IC50 values of 0.43, 0.036, 0.041, 0.095, and 1.04 μM. Additionally, IDO/Tubulin-IN-2 markedly enhances antitumor activity [1].

IDO/Tubulin-IN-2 (HT2) (0-50 μM, 4 h) 对癌细胞系表现出显著细胞毒性，IC 50 值介于0.036至0.43 μM [1]。IDO/Tubulin-IN-2 (0.1 μM, 24 h) 主要使HepG2细胞周期在G2期停滞 [1]。同一条件下，它能有效引发细胞凋亡 [1]，显著促进PARP的蛋白水解切割并上调caspase-3表达水平 [1]。IDO/Tubulin-IN-2在更长时间（0.05 μM, 24, 48, 72 h）显著降低TDO mRNA表达水平，呈现时间依赖效应 [1]。连续处理2天，能够提升T细胞的活化和增殖，增强免疫反应 [1]。

IDO/Tubulin-IN-2（HT2）（30 mg/kg；静脉注射；每天，持续21天）显著抑制肿瘤生长[1]。经静脉注射30 mg/kg的IDO/Tubulin-IN-2，连续29天的治疗，可有效激发肿瘤免疫力，提升肿瘤疗效[1]。